Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults

Reuters

06-01

Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults

Seer Inc. (Nasdaq: SEER) has announced the launch of a large-scale clinical study in collaboration with Korea University, aimed at identifying novel blood-based biomarkers for early cancer detection in young adults. The study will utilize Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument, along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, to conduct deep, unbiased proteomic analysis of 20,000 plasma samples. This includes samples from 15,000 cancer patients and 5,000 healthy controls. The study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea. This initiative supports ambitious health research and seeks to develop AI-driven diagnostics for cancers in individuals in their 20s and 30s.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9460983-en) on June 01, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540731894"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540731894\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540731894?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-01 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540731894","market":"nz","top_or_hot":-1,"title":"Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Seer Inc. (Nasdaq: SEER) has announced the launch of a large-scale clinical study in collaboration with Korea University, aimed at identifying novel blood-based biomarkers for early cancer detection in young adults. The study will utilize Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument, along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, to conduct deep, unbiased proteomic analysis of 20,000 plasma samples. This includes samples from 15,000 cancer patients and 5,000 healthy controls. The study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea. This initiative supports ambitious health research and seeks to develop AI-driven diagnostics for cancers in individuals in their 20s and 30s.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9460983-en) on June 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSeer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-01 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Seer Inc. (Nasdaq: SEER) has announced the launch of a large-scale clinical study in collaboration with Korea University, aimed at identifying novel blood-based biomarkers for early cancer detection in young adults. The study will utilize Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument, along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, to conduct deep, unbiased proteomic analysis of 20,000 plasma samples. This includes samples from 15,000 cancer patients and 5,000 healthy controls. The study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea. This initiative supports ambitious health research and seeks to develop AI-driven diagnostics for cancers in individuals in their 20s and 30s.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9460983-en) on June 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和數據","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nNDL4qK97T:1","article_id":"2540731894","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540731894","pubTimestamp":1748775617,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults. Seer Inc.  has announced the launch of a large-scale clinical study in collaboration with Korea University, aimed at identifying novel blood-based biomarkers for early cancer detection in young adults. The study will utilize Seer's newly launched Proteograph ONE Assay and SP200 Automation Instrument, along with the Thermo Scientific Orbitrap Astral mass spectrometer, to conduct deep, unbiased proteomic analysis of 20,000 plasma samples. This includes samples from 15,000 cancer patients and 5,000 healthy controls. The study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea. This initiative supports ambitious health research and seeks to develop AI-driven diagnostics for cancers in individuals in their 20s and 30s.Disclaimer: This news brief was created by Public Technologies  using generative","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4121":"生命科学工具和服务","SEER":"Seer, Inc.","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Seer Inc.与高丽大学启动突破性的20,000个样本蛋白质组学研究，为年轻人开发人工智能驱动的癌症诊断","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"SEER":0.9},"content_text":"Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults\n    \n\n        Seer Inc. (Nasdaq: SEER) has announced the launch of a large-scale clinical study in collaboration with Korea University, aimed at identifying novel blood-based biomarkers for early cancer detection in young adults. The study will utilize Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument, along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, to conduct deep, unbiased proteomic analysis of 20,000 plasma samples. This includes samples from 15,000 cancer patients and 5,000 healthy controls. The study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea. This initiative supports ambitious health research and seeks to develop AI-driven diagnostics for cancers in individuals in their 20s and 30s.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9460983-en) on June 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}